Skip to main content
TEYI PHARMACEUTICAL GROUP CO.,LTD logo

TEYI PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002728 ISIN · CNE100001WK6 LEI · 300300ZUIZCFPGQWOZ61 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,596 across all filing types
Latest filing 2024-06-11 Share Issue/Capital Cha…
Country CN China
Listing Shenzhen Stock Exchange 002728

About TEYI PHARMACEUTICAL GROUP CO.,LTD

https://www.tczy.com.cn

TEYI PHARMACEUTICAL GROUP CO.,LTD. specializes in the research, development, manufacturing, and distribution of pharmaceutical products. The company's portfolio primarily consists of Chinese patent medicines and chemical drug preparations. Its flagship product, Zhike Bao Tablets, is widely recognized for treating chronic bronchitis and cough-related ailments. Beyond respiratory health, the group produces a diverse range of medications covering cardiovascular diseases, gastrointestinal disorders, and anti-infective treatments. Teyi Pharmaceutical operates modern production facilities and maintains a robust distribution network to serve healthcare providers and pharmacies. The company emphasizes the integration of traditional medicinal knowledge with modern pharmaceutical technology to enhance product efficacy and safety.

Recent filings

Filing Released Lang Actions
关于控股股东、实际控制人、董事长提议公司回购股份的公告
Share Issue/Capital Change Classification · 95% confidence The document is an announcement from the company regarding a proposal by the controlling shareholder and chairman to repurchase company shares. It details the proposal's background, purpose, terms, and the board's approval of the share repurchase plan. There are no financial statements or detailed financial performance data included. The document is focused on the company's share buyback plan, which is a capital structure change. Therefore, it fits the category of a Share Issue/Capital Change announcement rather than a full financial report or other types of filings.
2024-06-11 Chinese
关于回购公司股份方案的公告
Transaction in Own Shares Classification · 100% confidence The document is a detailed announcement regarding a company's share repurchase plan, including specifics on the repurchase amount, price, purpose (for equity incentives or employee stock ownership plans), implementation period, funding source, and risk disclosures. It also includes board meeting resolutions approving the repurchase plan and compliance with regulatory requirements. The document does not contain financial statements or quarterly/yearly financial results but focuses on the company's plan to buy back its own shares. This matches the definition of a Transaction in Own Shares (POS) filing, which covers announcements of share repurchase programs. The document length is sufficient and contains substantive details about the repurchase plan, not just a brief notice or a report publication announcement. Therefore, the correct classification is POS with high confidence.
2024-06-11 Chinese
关于第五届董事会第二十三次会议决议的公告
Transaction in Own Shares Classification · 95% confidence The document is an announcement of the resolutions passed at a board of directors meeting, specifically the approval of a share repurchase plan. It details the meeting date, attendance, and voting results. The content focuses on board decisions rather than full financial statements or detailed financial performance. The document length is short (968 characters) and it is a formal announcement of a board meeting resolution, not a full report or financial statement. Therefore, it fits best under 'Transaction in Own Shares' (POS) as it announces a share buyback plan approved by the board.
2024-06-11 Chinese
关于第五届监事会第二十一次会议决议的公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of a resolution passed at the 21st meeting of the 5th Supervisory Board of 特一药业集团股份有限公司. It details the approval of a proposal regarding the temporary use of idle raised funds from convertible bonds to supplement working capital. The document includes meeting attendance, voting results, and compliance with relevant laws and regulations. It does not contain financial statements or detailed financial performance data, nor is it a report or presentation. It is an official announcement related to the company's use of raised funds and internal supervisory board decisions. This fits best under Regulatory Filings (RNS) as it is a regulatory announcement about fund usage and board resolutions without being a full financial report or other specific filing type.
2024-05-10 Chinese
关于使用可转债部分闲置募集资金暂时补充流动资金的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by 特一药业集团股份有限公司 regarding the temporary use of idle funds raised from convertible bonds to supplement working capital. It details the approval by the board, the amount of funds involved, the regulatory approvals, and assurances that the use of funds does not change the original purpose of the raised capital. The document includes references to regulatory compliance and opinions from the supervisory board and sponsoring institution. The content is focused on a financing update related to the use of raised capital and does not contain financial statements or detailed financial results. The document length is under 5,000 characters and is an announcement rather than a full report. Therefore, it fits best under Capital/Financing Update (CAP).
2024-05-10 Chinese
东莞证券股份有限公司关于特一药业集团股份有限公司使用可转债部分闲置募集资金暂时补充流动资金的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed verification opinion from Dongguan Securities regarding the use of idle raised funds from convertible bonds by Te Yi Pharmaceutical Group Co., Ltd. It discusses regulatory compliance, fund usage, approvals by the board and supervisory committee, and the rationale for temporarily supplementing working capital with idle raised funds. The document references regulatory guidelines and approvals but does not contain financial statements or quarterly/yearly financial results. It is a formal verification or audit-type opinion related to the use of funds raised via convertible bonds, focusing on compliance and appropriateness of fund usage. This fits the definition of an Audit Report / Information (AR) rather than an announcement, report publication, or financial report. The document length is 3172 characters, which is relatively short but contains substantive content beyond a mere announcement or certification. Therefore, the best classification is AR with high confidence. FY 2024
2024-05-10 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.